This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n4http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064203%3A_____%2F11%3A7013%21RIV12-MZ0-00064203/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n8http://linked.opendata.cz/resource/domain/vavai/subjekt/
n7http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n18http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064203%3A_____%2F11%3A7013%21RIV12-MZ0-00064203
rdf:type
skos:Concept n7:Vysledek
rdfs:seeAlso
http://www.ncbi.nlm.nih.gov/pubmed/21212791
dcterms:description
We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS. Leukemia (2011) 25, 455-462; doi:10.1038/leu.2010.297; published online 7 January 2011 We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS. Leukemia (2011) 25, 455-462; doi:10.1038/leu.2010.297; published online 7 January 2011
dcterms:title
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study
skos:prefLabel
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study
skos:notation
RIV/00064203:_____/11:7013!RIV12-MZ0-00064203
n7:predkladatel
n8:ico%3A00064203
n3:aktivita
n9:I
n3:aktivity
I
n3:cisloPeriodika
3
n3:dodaniDat
n18:2012
n3:domaciTvurceVysledku
n17:4977939 n17:1891871
n3:druhVysledku
n11:J
n3:duvernostUdaju
n16:S
n3:entitaPredkladatele
n4:predkladatel
n3:idSjednocenehoVysledku
201874
n3:idVysledku
RIV/00064203:_____/11:7013
n3:jazykVysledku
n6:eng
n3:klicovaSlova
myelodysplastic syndrome; stem cell transplantation; children; acute myeloid-leukemia; juvenile myelomonocytic leukemia; bone-marrow-transplantation; versus-host-disease; childhood; graft; classification; experience; survival; therapy
n3:klicoveSlovo
n5:experience n5:juvenile%20myelomonocytic%20leukemia n5:survival n5:bone-marrow-transplantation n5:myelodysplastic%20syndrome n5:childhood n5:therapy n5:versus-host-disease n5:acute%20myeloid-leukemia n5:graft n5:stem%20cell%20transplantation n5:classification n5:children
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[7A129A2A4824]
n3:nazevZdroje
Leukemia
n3:obor
n15:FD
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
21
n3:rokUplatneniVysledku
n18:2011
n3:svazekPeriodika
25
n3:tvurceVysledku
Strahm, B. Starý, Jan Sedláček, Petr Trebo, M. Locatelli, F. O\'Marcaigh, A. Nollke, P. van den Heuvel-Eibrink, MM Wojcik, D. de Heredia, CD Bierings, M. Moerloose, BD Schmugge, M. Bordon, V. Zecca, M. Niemeyer, CM Bergstraesser, E. Chybicka, A. Furlan, I. Peters, C. Korthof, ET
n3:wos
000288159500008
s:issn
0887-6924
s:numberOfPages
8